A1P0 Stock Overview
Engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Acasti Pharma Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.40 |
| 52 Week High | US$3.33 |
| 52 Week Low | US$1.63 |
| Beta | 1.56 |
| 1 Month Change | -10.45% |
| 3 Month Change | -20.53% |
| 1 Year Change | n/a |
| 3 Year Change | -87.18% |
| 5 Year Change | -93.41% |
| Change since IPO | -99.35% |
Recent News & Updates
Recent updates
Shareholder Returns
| A1P0 | DE Pharmaceuticals | DE Market | |
|---|---|---|---|
| 7D | -3.2% | -0.7% | -0.5% |
| 1Y | n/a | -20.1% | 5.2% |
Return vs Industry: Insufficient data to determine how A1P0 performed against the German Pharmaceuticals industry.
Return vs Market: Insufficient data to determine how A1P0 performed against the German Market.
Price Volatility
| A1P0 volatility | |
|---|---|
| A1P0 Average Weekly Movement | 5.9% |
| Pharmaceuticals Industry Average Movement | 5.5% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 10.7% |
| 10% least volatile stocks in DE Market | 2.5% |
Stable Share Price: A1P0's share price has been volatile over the past 3 months.
Volatility Over Time: A1P0's weekly volatility has decreased from 12% to 6% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2002 | n/a | Prashant Kohli | www.acastipharma.com |
Acasti Pharma Inc. engages in the development and commercialization of pharmaceutical products for rare and orphan diseases in Canada. The company’s lead product candidate is the GTX-104, an intravenous infusion to treat subarachnoid hemorrhage. It also develops GTX-102, an oral mucosal spray for the treatment of ataxia-telangiectasia; and GTX-101, a topical bioadhesive film-forming bupivacaine spray for postherpetic neuralgia.
Acasti Pharma Inc. Fundamentals Summary
| A1P0 fundamental statistics | |
|---|---|
| Market cap | €23.56m |
| Earnings (TTM) | -€35.74m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.7x
P/E RatioIs A1P0 overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| A1P0 income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$38.77m |
| Earnings | -US$38.77m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -4.13 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did A1P0 perform over the long term?
See historical performance and comparison